Sutro Biopharma Inc

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Sutro Biopharma expects to report interim results from a phase 1 study using STRO-002 at KOL event on Wednesday Jan. 5, 2022, at 5 p.m. ET.

Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching

SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Dec. 27, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced an exclusive license agreement with Tasly Biopharmaceuticals Co., Ltd.

Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

SOUTH SAN FRANCISCO, Calif., Dec. 27, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro"), (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced today that it will provide interim data from the Company's ongoing dose-expansion cohort of the Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC), for patients with advanced ovarian cancer, at a Company hosted KOL virtual event.

Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer

SOUTH SAN FRANCISCO, Calif, Dec. 13, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that its research collaborators at the Fred Hutchinson Cancer Research Center presented nonclinical data of STRO-002 and STRO-001 in two oral presentations at the 63rd American Society of Hematology Annual Meeting (ASH 2021) in Atlanta, Georgia. The research was conducted by investigators from the laboratory of Soheil Meshinchi, M.D.

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will participate in two upcoming virtual investor conferences.

Sutro Biopharma to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Nov. 17, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Heidi Hunter has been appointed to Sutro's Board of Directors. "Heidi is an accomplished leader with considerable experience driving the successful development and commercialization of new medicines," said Bill Newell, Chief Executive Officer of Sutro.

Sutro Biopharma Announces Appointment of Heidi Hunter to Board of Directors

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today reported its financial results for the quarter ended September 30, 2021, its recent business highlights, and a preview of anticipated select milestones in the remainder of 2021.

Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will participate in three upcoming virtual investor conferences.

Sutro Biopharma to Participate in Three Upcoming Investor Conferences

SAN FRANCISCO and SHANGHAI, Oct. 12, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, and BioNova Pharmaceuticals Limited (BioNova), a company dedicated to the discovery, development and commercialization of innovative medicines for the treatment of diseases with unmet medical needs, today jointly announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate (ADC), for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan. Under the terms of the agreement, BioNova has the option to obtain exclusive rights to develop and commercialize STRO-001 in Greater China.

Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China

Merck

Merck & Co Inc (NYSE: MRK) has extended the research term by two years for the first cytokine derivative program under a 2018 agreement with Sutro Biopharma Inc (NASDAQ: STRO). The research extension is intended to facilitate preclinical research and development activities for a second candidate with a novel design and approach.

Merck, Sutro Biopharma Extends Cytokine Derivative Research Program

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Merck, known as MSD outside the United States and Canada, has extended the research term for the first cytokine derivative program under the 2018 Merck Agreement, for an additional two years.

Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced today the appointment of two executives to the Company's leadership team.

Sutro Biopharma Announces Expansion of Leadership Team

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Bill Newell, Chief Executive Officer, will participate in the 2021 Wells Fargo Securities Healthcare Conference during a virtual fireside chat on Thursday, September 9, at 3:20 p.m.

Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

Sutro's (STRO) investigational antibody-drug conjugate therapy, STRO-002, gets Fast Track designation from the FDA for advanced ovarian cancer.

Sutro (STRO) Ovarian Cancer Drug Gets FDA's Fast Track Tag

The FDA has granted Fast Track designation to Sutro Biopharma Inc's (NASDAQ: STRO) STRO-002 for ovarian cancer. The designation covers platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients who have received one to three prior lines of systemic therapy.

Sutro Biopharma's Ovarian Cancer Candidate Fast Tracked In US

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for STRO-002, a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of systemic therapy.

Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Aug. 9, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today reported its financial results for the quarter ended June 30, 2021, its recent business highlights, and provided a preview of anticipated selected milestones in the second half of 2021.

Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones

SOUTH SAN FRANCISCO, Calif., Aug. 9, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the appointment of Jane Chung to the newly-created position of Chief Commercial Officer, effective August 9, 2021.

Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer

Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Sutro Biopharma, Inc. (STRO) Report Negative Q2 Earnings? What You Should Know

SOUTH SAN FRANCISCO, Calif., July 29, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will participate in a panel titled "ADCs – Take Me to Your Tumor" at the 12th Annual Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11, at 2:20 p.m.

Sutro Biopharma to Participate in the 12th Annual Wedbush PacGrow Healthcare Virtual Conference

Sutro Biopharma, Inc. (STRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sutro Biopharma, Inc. (STRO) Surges 6.4%: Is This an Indication of Further Gains?

SOUTH SAN FRANCISCO, Calif., June 15, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will participate in two virtual investor conferences in June.

Sutro Biopharma to Participate in Two Virtual Investor Conferences in June

Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA Germany (OTC: MKGAF). The payment is related to a patient enrollment achievement in the Phase 1 dose-escalation and expansion study of M1231 in adult patients with metastatic solid tumors.

Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck

SOUTH SAN FRANCISCO, Calif., June 1, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that it has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany, related to a patient enrollment achievement in the Phase 1 dose escalation and expansion study of M1231 in adult patients with metastatic solid tumors, including non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma.

Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany

SOUTH SAN FRANCISCO, Calif., May 19, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced additional data from the Company's dose-escalation cohort of the Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) for patients with advanced, progressive ovarian cancer; the data will also be presented as a poster at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting to be held on June 4-8, 2021.

News for Sutro Biopharma Inc Stock (STRO)